Logo image of NTRA

NATERA INC (NTRA) Stock Price, Quote, News and Overview

NASDAQ:NTRA - Nasdaq - US6323071042 - Common Stock - Currency: USD

153.79  -0.69 (-0.45%)

After market: 153.79 0 (0%)

NTRA Quote, Performance and Key Statistics

NATERA INC

NASDAQ:NTRA (4/25/2025, 9:25:24 PM)

After market: 153.79 0 (0%)

153.79

-0.69 (-0.45%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High183
52 Week Low90.88
Market Cap20.79B
Shares135.19M
Float130.00M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07/amc
IPO07-02 2015-07-02


NTRA short term performance overview.The bars show the price performance of NTRA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

NTRA long term performance overview.The bars show the price performance of NTRA in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of NTRA is 153.79 USD. In the past month the price increased by 3.7%. In the past year, price increased by 67.78%.

NATERA INC / NTRA Daily stock chart

NTRA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B
UTHR UNITED THERAPEUTICS CORP 11.84 13.09B

About NTRA

Company Profile

NTRA logo image Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Company Info

NATERA INC

13011 Mccallen Pass, Building A Suite 100

Austin TEXAS 78753 US

CEO: Steve Chapman

Employees: 3288

Company Website: https://www.natera.com/

Investor Relations: https://investor.natera.com

Phone: 16502499090

NATERA INC / NTRA FAQ

What is the stock price of NATERA INC today?

The current stock price of NTRA is 153.79 USD. The price decreased by -0.45% in the last trading session.


What is the ticker symbol for NATERA INC stock?

The exchange symbol of NATERA INC is NTRA and it is listed on the Nasdaq exchange.


On which exchange is NTRA stock listed?

NTRA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NATERA INC stock?

27 analysts have analysed NTRA and the average price target is 199.97 USD. This implies a price increase of 30.03% is expected in the next year compared to the current price of 153.79. Check the NATERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NATERA INC worth?

NATERA INC (NTRA) has a market capitalization of 20.79B USD. This makes NTRA a Large Cap stock.


How many employees does NATERA INC have?

NATERA INC (NTRA) currently has 3288 employees.


What are the support and resistance levels for NATERA INC (NTRA) stock?

NATERA INC (NTRA) has a support level at 151.31 and a resistance level at 153.8. Check the full technical report for a detailed analysis of NTRA support and resistance levels.


Is NATERA INC (NTRA) expected to grow?

The Revenue of NATERA INC (NTRA) is expected to grow by 15.92% in the next year. Check the estimates tab for more information on the NTRA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NATERA INC (NTRA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NATERA INC (NTRA) stock pay dividends?

NTRA does not pay a dividend.


When does NATERA INC (NTRA) report earnings?

NATERA INC (NTRA) will report earnings on 2025-05-07, after the market close.


What is the Price/Earnings (PE) ratio of NATERA INC (NTRA)?

NATERA INC (NTRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).


What is the Short Interest ratio of NATERA INC (NTRA) stock?

The outstanding short interest for NATERA INC (NTRA) is 4.29% of its float. Check the ownership tab for more information on the NTRA short interest.


NTRA Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to NTRA. When comparing the yearly performance of all stocks, NTRA is one of the better performing stocks in the market, outperforming 94.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NTRA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to NTRA. While NTRA has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NTRA Financial Highlights

Over the last trailing twelve months NTRA reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 59.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -11.47%
ROE -15.93%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%35.94%
Sales Q2Q%53.04%
EPS 1Y (TTM)59.63%
Revenue 1Y (TTM)56.74%

NTRA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to NTRA. The Buy consensus is the average rating of analysts ratings from 27 analysts.

For the next year, analysts expect an EPS growth of -43.9% and a revenue growth 15.92% for NTRA


Ownership
Inst Owners92.42%
Ins Owners3.53%
Short Float %4.29%
Short Ratio3.07
Analysts
Analysts86.67
Price Target199.97 (30.03%)
EPS Next Y-43.9%
Revenue Next Year15.92%